我们的结果显示医院药物不良反应的总体负担很高，因此为减少这个现象，需要采用新的干预方法。
Our results show that the overall burden of ADRs on hospitals is high and therefore new methods of intervention are needed to reduce this.
在服用一种新的药物时，要仔细阅读说明书，看该药是否会引起皮肤系统相关的不良反应。
Whenever you start taking a new medicine, read the label closely to see if you should expect any dermatological side effects.
因此，病人又出现了其他新的症状，因为这些其他途径引起了不良反应。
Hence, the patient will experience new symptoms as these other pathways elicit undesired effects.
这些发现为DILI机制研究带来新的视角，而且有助于确定发生这种严重不良反应风险较大的患者。
These findings provide new insights into the mechanism of DILI and have the potential to help identify individuals who may have an increased risk for this serious event.
结论黛力新与雷贝拉唑对功能性消化不良的近期及维持治疗均有良好疗效，无明显不良反应，值得临床推广使用。
Conclusion Deanxit and rabeprazole on functional dyspepsia and maintenance treatment of recent have a good effect, no significant adverse reactions, is worthy of clinical use.
目的：综述新氟喹诺酮类抗生素的各种不良反应，为临床合理用药提供依据。
Objective: to review various adverse reactions of new fluoroquinolones in order to provide the basis for clinical rational drug use.
结论：通过这种方法可及时获得药物性肝损害发生的信息，同时这也为医院集中开展药物不良反应监测提供了一种新的思路。
CONCLUSION: By this way, we can timely get the information of drug-induced liver damage and set up a new way for developing centralized ADR monitoring in hospital.
目的了解内皮素- 1 (et - 1)对小梁细胞收缩状态调节的作用方式，以求探索新的有效而不良反应小的抗青光眼药物。
Objective to find out the method of ET-1 in regulating trabecular meshwork cell (TMC) contraction and to explore new effective drug treating glaucoma with little side-effects.
目的构建一种新的药品不良反应(adr)因果关系判定的量化标准。
Objective To explore a quantitative method of causality assessment of adverse drug reactions (ADR).
该药处方信息中的警告和不良反应栏目已做了修订，以反映这一新的安全信息。
The WARNINGS and ADVERSE REACTIONS sections of the CellCept Prescribing Information have been revised to reflect this new safety information.
Makhija说到这种新的联合疗法可增加复发患者生存期的周数，而药物也较易为病人耐受且仅引起轻微不良反应。
Makhija said the new combination added weeks to the standard survival period for recurrent patients, and the drug combo was well-tolerated by the body and caused minimal side effects.
新一代药物不良反应较少，治疗PDPN提供了新的选择。
New agents with few adverse effects provide new choices for treatment of PDPN.
目前药品不良反应报告存在着“药品不良反应报告少，新的和严重的药品不良反应报告少，药品生产企业药品不良反应报告少”的现状。
Now, "ADR are few reported, especially new and severe ADR reports are few, the ADR reported by drug production enterprises are also few".
国外研究显示，新的药物包括新的支气管扩张剂和抗炎新药，将更好地治疗哮喘，减少不良反应，增加患者依从性。
Since the advances of clinical studies, some new anti-inflammatory drugs and bronchodilators with less adverse reaction, better effect and compliance are in development stage.
由于目前的药物起效慢和不良反应多，临床疗效仍不满意，多靶点、多系统共同作用类药物已成为新的研究方向。
They still can not meet clinical needs with respect to both efficacy and side effects. A diversity of multi-target strategies are proposed for the future generation of successful antidepressants.
结论应加强adr的监测和ADR知识的宣传，避免或减少其重复发生，对新的、严重的不良反应应引起重视。
Conclusion the monitoring and knowledge of ADR can be strengthened and avoid or reduce the recurrence. We will pay attention to the new or serious ADR.
由于药效短和较好的风险利益关系，该药已成为抗高血压治疗的新选择。现对其药理作用、临床研究及不良反应等做一综述。
When oral drug therapy is not appropriate for blood pressure control, its rapid action and good benefit-to-risk profile may be a good alternative for antihypertensive treatment.
由于药效短和较好的风险利益关系，该药已成为抗高血压治疗的新选择。现对其药理作用、临床研究及不良反应等做一综述。
When oral drug therapy is not appropriate for blood pressure control, its rapid action and good benefit-to-risk profile may be a good alternative for antihypertensive treatment.
应用推荐